Highlights
- Volpara’s technology supports breast-density analysis and screening workflows.
- Lunit integrated Volpara operations following its May 2024 acquisition.
- An April 2026 update cited deployments at more than 330 sites.
- A 2026 report identified over 3,600 institutions using former Volpara capabilities.
Volpara Health Technologies (ASX:VHT) developed software used in breast screening to assess breast density, support risk evaluation and help imaging providers manage clinical workflows. Its technology is now part of Lunit’s wider breast-imaging ecosystem, which combines analytical tools with AI-assisted detection. The most useful recent evidence is not a standalone financial forecast for Volpara but the operational and clinical reach described in its parent company’s 2026 disclosures.
Breast Density and Workflow Data Remain Central
Volpara’s software was designed to address practical problems in breast screening: measuring breast density consistently, improving imaging quality and coordinating reporting or follow-up. Breast density is relevant to screening because dense tissue can complicate interpretation and contributes information used in risk assessment. Automated analysis can make measurements more consistent, but clinical judgement and applicable screening protocols remain necessary.
Lunit’s product portfolio combines those functions with AI-based image analysis for mammography and digital breast tomosynthesis. The pairing means a healthcare provider may use one set of tools to assess image quality and density while another examines imaging findings. Their clinical functions are complementary rather than interchangeable.
2026 Adoption Provides a Scale Indicator
In April 2026, Lunit described deployments across more than 330 sites and referenced more than one million annual breast screenings in its clinical adoption update. It also described a Lexington Clinic implementation covering AI detection, quality optimisation and Volpara Live. These counts illustrate operational reach across the group’s breast-imaging offerings; they should not be interpreted as Volpara-only customer additions or independent Volpara revenue.
A separate first-quarter 2026 Lunit Business report described the former Volpara operation’s distribution network as reaching more than 9,500 healthcare professionals across over 3,600 institutions worldwide. Such numbers help explain why existing customer relationships matter in medical technology. However, professionals, institutions and deployment sites are different denominators, and direct comparisons across those measures would be misleading.
One Brand Across Detection and Risk Assessment
Lunit announced in November 2025 that Volpara would operate under the Lunit brand. It described a unified proposition spanning risk prediction, early detection, imaging quality and precision medicine. The operational structure included Lunit International, representing former Volpara operations across several regions, and Lunit Americas for the North and South American markets.
That integration offers a clearer route for Marketing complementary technology, but product compatibility and clinical procurement still determine adoption. Hospitals may require evidence on workflow efficiency, reliability and patient outcomes before deploying new AI tools. Data handling rules and regulatory approvals can differ among markets, so international distribution does not automatically mean every product is available for every clinical use.
Contract History and Clinical Evidence
In November 2024, the former Volpara business announced a United States Defense Health Agency contract valued at USD 7.3 million over five years for its Patient Hub platform. This is a historically disclosed multi-year arrangement, not a newly awarded 2026 contract. It illustrates the role of patient tracking, risk assessment and reporting alongside image analysis.
Lunit also reported in March 2025 that Volpara density measurements had been validated as an input to the BOADICEA breast cancer risk model. The company later described new enterprise deployments and regulatory milestones for detection technology. Continuing evaluation will depend on clinical effectiveness, privacy and integration costs.
Key Insights
Volpara’s breast-density, quality and reporting tools contribute to Lunit’s connected screening ecosystem. Parent-company updates in 2026 described more than 330 deployment sites and a former Volpara network spanning over 3,600 institutions. These are measures of group reach and distribution, not standalone Volpara earnings.



_11_16_2026_11_23_12_237620.jpg)


Please wait processing your request...